Skip to Content
Merck
CN
  • Paraoxonase 1 genotype-phenotype correlation in patients with metabolic syndrome.

Paraoxonase 1 genotype-phenotype correlation in patients with metabolic syndrome.

Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie (2015-07-21)
Lorena Ciumărnean, Eleonora Dronca, Ştefan Cristian Vesa, Dorel Sâmpelean, Anca Dana Buzoianu, Andrei Achimaş-Cadariu
ABSTRACT

The aim of the study was to investigate the influence of three single nucleotide polymorphisms (SNPs) (-108C>T, -162A>G and -909G>C) from the promoter region of paraoxonase 1 (PON1) gene on the enzyme activity, in patients with metabolic syndrome (MS). The study group consisted of 61 individuals with MS and the control group of 73 individuals without MS, matched for age and gender. For each individual, clinical and genetic parameters with possible influence on PON1 activities (paraoxonase, arylesterase and lactonase) were measured. PON1 genotyping was performed with PCR-RFLP, using specific primers and restriction enzymes. We found no differences for distribution of PON1 -108C>T, -162A>G and -909G>C polymorphisms, between the two groups (p-NS). The -108C>T and -909G>C polymorphisms were associated with paraoxonase (p=0.03, p=0.006, respectively), arylesterase (p<0.001, p<0.001, respectively) and lactonase (p<0.001, p<0.001, respectively) activities. The -162A>G polymorphism was not associated with paraoxonase (p-NS) or lactonase (p-NS) activities, but influenced the arylesterase activity (p=0.03). PON1 activities were influenced by all three polymorphisms, regardless of the presence of MS.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Paraoxon-ethyl, ≥90%, oil
Sigma-Aldrich
Phenyl acetate, 99%